

# Paul C Dinh

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7293528/publications.pdf>

Version: 2024-02-01

43  
papers

700  
citations

759233

12  
h-index

580821

25  
g-index

43  
all docs

43  
docs citations

43  
times ranked

1022  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ototoxicity After Cisplatin-Based Chemotherapy: Factors Associated With Discrepancies Between Patient-Reported Outcomes and Audiometric Assessments. <i>Ear and Hearing</i> , 2022, 43, 794-807.	2.1	13
2	Re: Thyroid hypofunction in aging testicular cancer survivors. <i>Acta Oncologica</i> , 2022, 61, 386-387.	1.8	1
3	Pharmacogenomics of cisplatin-induced neurotoxicities: Hearing loss, tinnitus, and peripheral sensory neuropathy. <i>Cancer Medicine</i> , 2022, 11, 2801-2816.	2.8	14
4	Impact of adverse health outcomes (AHOs) on self-reported physical and mental health in U.S. testicular cancer survivors (TCS).. <i>Journal of Clinical Oncology</i> , 2022, 40, 12080-12080.	1.6	0
5	Cisplatin-induced tinnitus (CIS-TINN) and patient-reported outcomes in adult-onset cancer survivors.. <i>Journal of Clinical Oncology</i> , 2022, 40, e24089-e24089.	1.6	0
6	Epigenetic age acceleration in U.S. testicular cancer survivors (TCS).. <i>Journal of Clinical Oncology</i> , 2022, 40, 5033-5033.	1.6	1
7	Building a model to predict the risk of multiple severe neurotoxicities in cancer survivors after cisplatin treatment.. <i>Journal of Clinical Oncology</i> , 2022, 40, e24066-e24066.	1.6	0
8	Impact of cisplatin-induced hearing loss (CIHL) on patient-reported social and emotional functioning.. <i>Journal of Clinical Oncology</i> , 2022, 40, 12120-12120.	1.6	0
9	Use of Medications for Treating Anxiety or Depression among Testicular Cancer Survivors: A Multi-Institutional Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1129-1138.	2.5	4
10	Pharmacogenomics of cisplatin-induced neurotoxicities: Hearing loss, tinnitus and peripheral sensory neuropathy.. <i>Journal of Clinical Oncology</i> , 2021, 39, 12004-12004.	1.6	0
11	Effect of pretreatment central adiposity on the cardiometabolic risk of male germ cell tumor survivors after cisplatin-based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, 5019-5019.	1.6	0
12	Hearing loss after cisplatin-based chemotherapy: Patient-reported outcomes versus audiometric assessments.. <i>Journal of Clinical Oncology</i> , 2021, 39, 5016-5016.	1.6	1
13	Integration of a polygenic risk score of kidney function with cumulative cisplatin dose and time variables for the prediction of serum platinum levels.. <i>Journal of Clinical Oncology</i> , 2021, 39, 12063-12063.	1.6	1
14	Factors associated with use of medications for anxiety and depression in testicular cancer survivors after cisplatin-based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, 5025-5025.	1.6	2
15	Risk Patterns and Mortality in Postmenopausal Women Using Latent Class Analysis. <i>American Journal of Preventive Medicine</i> , 2021, 61, e225-e233.	3.0	4
16	Cisplatin, environmental metals, and cardiovascular disease: an urgent need to understand underlying mechanisms. <i>Cardio-Oncology</i> , 2021, 7, 34.	1.7	4
17	Adverse Health Outcomes Among US Testicular Cancer Survivors After Cisplatin-Based Chemotherapy vs Surgical Management. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz079.	2.9	12
18	The role of reproductive coercion in women's risk for HIV: A case-control study of outpatients in Gauteng, South Africa. <i>International Journal of Gynecology and Obstetrics</i> , 2020, 151, 377-382.	2.3	4

#	ARTICLE	IF	CITATIONS
19	Relationship of Cisplatin-Related Adverse Health Outcomes With Disability and Unemployment Among Testicular Cancer Survivors. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa022.	2.9	11
20	Solid and Hematologic Neoplasms After Testicular Cancer: A US Population-Based Study of 24,900 Survivors. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa017.	2.9	12
21	Lifestyle and Psychosocial Patterns and Diabetes Incidence Among Women with and Without Obesity: a Prospective Latent Class Analysis. <i>Prevention Science</i> , 2020, 21, 850-860.	2.6	4
22	Associations of adiponectin and leptin with brain natriuretic peptide in African Americans: the Jackson Heart Study. <i>Cardiovascular Endocrinology and Metabolism</i> , 2020, 9, 49-55.	1.1	3
23	Increased Risk of Cardiovascular Sequelae in Survivors of Male Germ Cell Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 1497-1498.	1.6	0
24	Associations of leptin and adiponectin with incident type 2 diabetes and interactions among African Americans: the Jackson heart study. <i>BMC Endocrine Disorders</i> , 2020, 20, 31.	2.2	21
25	The association between sleep duration and lipid profiles: the NHANES 2013-2014. <i>Journal of Diabetes and Metabolic Disorders</i> , 2019, 18, 315-322.	1.9	28
26	Clinical and Genome-Wide Analysis of Serum Platinum Levels after Cisplatin-Based Chemotherapy. <i>Clinical Cancer Research</i> , 2019, 25, 5913-5924.	7.0	16
27	Clinical and Genome-wide Analysis of Cisplatin-induced Tinnitus Implicates Novel Ototoxic Mechanisms. <i>Clinical Cancer Research</i> , 2019, 25, 4104-4116.	7.0	27
28	Personality traits and the risk of coronary heart disease or stroke in women with diabetes – an epidemiological study based on the Women's Health Initiative. <i>Menopause</i> , 2019, Publish Ahead of Print, 1117-1124.	2.0	4
29	Physical activity and weight gain after smoking cessation in postmenopausal women. <i>Menopause</i> , 2019, 26, 16-23.	2.0	5
30	Smoking cessation, weight gain, and risk of stroke among postmenopausal women. <i>Preventive Medicine</i> , 2019, 118, 184-190.	3.4	17
31	Genetic and Modifiable Risk Factors Contributing to Cisplatin-induced Toxicities. <i>Clinical Cancer Research</i> , 2019, 25, 1147-1155.	7.0	72
32	Adverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 459-468.	4.9	13
33	Testicular Cancer Survivorship. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1557-1568.	4.9	42
34	Second solid (SMN) and hematologic malignant neoplasms (HMN) among 24,900 United States testicular cancer survivors (TCS) after chemotherapy (CHEM), radiotherapy (RT), or surgery only (SURG).. <i>Journal of Clinical Oncology</i> , 2019, 37, 11573-11573.	1.6	1
35	Impact of cisplatin-related adverse health outcomes (AHOs) on employment outcomes and self-reported health (SRH) among testicular cancer survivors (TCS).. <i>Journal of Clinical Oncology</i> , 2019, 37, e16058-e16058.	1.6	0
36	Toxicities Associated with Cisplatin-Based Chemotherapy and Radiotherapy in Long-Term Testicular Cancer Survivors. <i>Advances in Urology</i> , 2018, 2018, 1-20.	1.3	81

#	ARTICLE	IF	CITATIONS
37	Clinical and Genetic Risk Factors for Adverse Metabolic Outcomes in North American Testicular Cancer Survivors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 257-265.	4.9	24
38	Pharmacokinetic (PK) modeling of serum platinum to reveal extent of long-term exposure and associated comorbidities after cisplatin treatment.. <i>Journal of Clinical Oncology</i> , 2018, 36, 10058-10058.	1.6	0
39	Association of Iodine and Iron with Thyroid Function. <i>Biological Trace Element Research</i> , 2017, 179, 38-44.	3.5	24
40	Adverse health outcomes in relationship to hypogonadism (HG) after platinum-based chemotherapy: A multicenter study of North American testicular cancer survivors (TCS).. <i>Journal of Clinical Oncology</i> , 2017, 35, LBA10012-LBA10012.	1.6	1
41	Adverse health outcomes in relationship to hypogonadism (HG) after platinum-based chemotherapy: A multicenter study of North American testicular cancer survivors (TCS).. <i>Journal of Clinical Oncology</i> , 2017, 35, LBA10012-LBA10012.	1.6	5
42	<i>Escherichia coli</i> Isolates That Carry <i>vat</i> , <i>fyuA</i> , <i>chuA</i> , and <i>yfcV</i> Efficiently Colonize the Urinary Tract. <i>Infection and Immunity</i> , 2012, 80, 4115-4122.	2.2	226
43	Associations of Body Fat Distribution and Cardiometabolic Risk of Testicular Cancer Survivors after Cisplatin-Based Chemotherapy. <i>JNCI Cancer Spectrum</i> , 0, , .	2.9	2